SUVN-502
- Generic Name
- SUVN-502
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24BrN3O3S
- CAS Number
- 701205-60-9
- Unique Ingredient Identifier
- 8XZ281AO3G
- Background
SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s and Schizophrenia, an unmet medical need.
- Indication
Investigated for use/treatment in neurologic disorders.
- Associated Conditions
- -
- Associated Therapies
- -
Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Suven Life Sciences Limited
- Registration Number
- NCT03564964
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 564
- Registration Number
- NCT02580305
- Locations
- 🇺🇸
Senior Clinical Trials, Inc., Laguna Hills, California, United States
🇺🇸Emerald Coast Center for Neurological Disorders, Pensacola, Florida, United States
🇺🇸Neurological Associates of Albany, PC, Albany, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath